Onizawa, MichioOshima, ShigeruSchulze-Topphoff, UlfOses-Prieto, Juan ALu, TimothyTavares, RitaProdhomme, ThomasDuong, BaoWhang, Michael I.Advincula, RommelAgelidis, AlexBarrera, JulioWu, HaoBurlingame, AlmaMalynn, Barbara A.Zamvil, Scott S.Ma, Averil2016-01-042015Onizawa, M., S. Oshima, U. Schulze-Topphoff, J. A. Oses-Prieto, T. Lu, R. Tavares, T. Prodhomme, et al. 2015. “The ubiquitin-modifying enzyme A20 restricts the ubiquitination of RIPK3 and protects cells from necroptosis.” Nature immunology 16 (6): 618-627. doi:10.1038/ni.3172. http://dx.doi.org/10.1038/ni.3172.1529-2908http://nrs.harvard.edu/urn-3:HUL.InstRepos:23993470A20 is an anti-inflammatory protein linked to multiple human diseases, however the mechanisms by which A20 prevents inflammatory disease are incompletely defined. We now find that A20 deficient T cells and fibroblasts are susceptible to caspase independent and RIPK3 dependent necroptosis. Global RIPK3 deficiency significantly rescues the survival of A20 deficient mice. A20 deficient cells exhibit exaggerated formation of RIPK1-RIPK3 complexes. RIPK3 undergoes physiological ubiquitination at lysine 5 (K5), and this ubiquitination event supports the formation of RIPK1-RIPK3 complexes. The catalytic cysteine of A20’s deubiquitinating motif is required for inhibiting RIPK3 ubiquitination and RIPK1-RIPK3 complex formation. These studies link A20 and RIPK3 ubiquitination to necroptotic cell death, and suggest new mechanisms by which A20 may prevent inflammatory disease.en-USJournal Article2016-01-0410.1038/ni.3172